FAM18A Activators
FAM18A, a Golgi apparatus membrane protein identified as TVP23 A, plays a crucial role in Golgi membrane dynamics and cellular processes related to vesicle trafficking and membrane organization. Activation of FAM18A is intricately linked to various chemical modulators that impact Golgi apparatus function indirectly by influencing membrane dynamics and associated cellular processes. One group of potential activators includes compounds like Brefeldin A, Monensin, and Wortmannin, which disrupt vesicle trafficking, perturb ion homeostasis, and inhibit PI3K, respectively. These actions could indirectly activate FAM18A by altering Golgi membrane properties and signaling pathways. Actin cytoskeleton modulators such as Jasplakinolide and Latrunculin B, along with microtubule inhibitors like Nocodazole, also hold the potential to influence FAM18A activation by impacting Golgi membrane dynamics through cytoskeletal modulation.
Compounds affecting ER-associated processes, such as Eeyarestatin I, DBeQ, and Geldanamycin, may indirectly activate FAM18A by influencing Golgi apparatus function through ERAD inhibition, p97/VCP inhibition, and Hsp90 inhibition, respectively. Additionally, inhibitors of membrane-associated processes, like GGTI-298 and PP2, might impact FAM18A by modulating the prenylation of membrane-associated proteins and Src kinase activity, respectively. Understanding the intricate interplay between these chemical modulators and FAM18A sheds light on potential regulatory mechanisms within the Golgi apparatus. The activation of FAM18A is a dynamic process influenced by multiple pathways and cellular processes, contributing to its role in membrane dynamics and cellular homeostasis within the Golgi apparatus.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Ionophore affecting intracellular ion concentration and membrane potential. Monensin's potential indirect activation of FAM18A involves perturbing ion homeostasis, impacting Golgi membrane properties. By influencing cellular ion dynamics, Monensin may alter the function of the Golgi apparatus and, in turn, modulate FAM18A activity related to Golgi membrane processes and intracellular trafficking. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Actin polymerization inhibitor impacting cytoskeletal dynamics. Jasplakinolide's potential indirect activation of FAM18A involves modulating the actin cytoskeleton, potentially influencing Golgi membrane dynamics. By affecting cytoskeletal organization, Jasplakinolide may impact cellular processes related to Golgi apparatus function, indirectly influencing FAM18A activity within the Golgi membrane environment. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Inhibitor of endoplasmic reticulum-associated protein degradation (ERAD). Eeyarestatin I may indirectly activate FAM18A by impacting ERAD processes, potentially influencing Golgi membrane dynamics. Its role in ERAD inhibition could modulate cellular pathways connected to Golgi apparatus function and contribute to FAM18A activation within the Golgi membrane environment. | ||||||
Latrunculin B | 76343-94-7 | sc-203318 | 1 mg | $240.00 | 29 | |
Actin polymerization inhibitor affecting cytoskeletal organization. Latrunculin B's potential indirect activation of FAM18A involves modulating the actin cytoskeleton, potentially influencing Golgi membrane dynamics. By impacting cytoskeletal organization, Latrunculin B may influence cellular processes related to Golgi apparatus function, indirectly activating FAM18A within the Golgi membrane environment. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Microtubule polymerization inhibitor impacting cytoskeletal organization. Nocodazole's potential indirect activation of FAM18A involves modulating the microtubule cytoskeleton, potentially influencing Golgi membrane dynamics. By affecting cytoskeletal organization, Nocodazole may impact cellular processes related to Golgi apparatus function, indirectly activating FAM18A within the Golgi membrane environment. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Actin polymerization inhibitor affecting cytoskeletal dynamics. Cytochalasin D's potential indirect activation of FAM18A involves modulating the actin cytoskeleton, potentially influencing Golgi membrane dynamics. By impacting cytoskeletal organization, Cytochalasin D may influence cellular processes related to Golgi apparatus function, indirectly activating FAM18A within the Golgi membrane environment. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
Geranylgeranyltransferase I (GGTase I) inhibitor influencing membrane-associated proteins. GGTI-298 may indirectly activate FAM18A by inhibiting GGTase I, impacting the prenylation of membrane-associated proteins. Its role in modulating membrane dynamics could influence Golgi apparatus function and contribute to FAM18A activation within the Golgi membrane environment. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Hsp90 inhibitor affecting protein folding. Geldanamycin's potential indirect activation of FAM18A involves inhibiting Hsp90, impacting protein folding and membrane-associated processes. By affecting chaperone-mediated protein folding, Geldanamycin may influence Golgi apparatus function and contribute to FAM18A activation within the Golgi membrane environment. Understanding the interplay between Hsp90 inhibition and FAM18A activation sheds light on potential regulatory mechanisms within the Golgi apparatus. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
Src family kinase inhibitor affecting cellular signaling. PP2's potential indirect activation of FAM18A involves Src kinase inhibition, impacting membrane-associated signaling pathways. Its role in modulating signaling cascades could influence Golgi apparatus function and contribute to FAM18A activation within the Golgi membrane environment. Understanding the interplay between Src kinase inhibition and FAM18A activation sheds light on potential regulatory mechanisms within the Golgi apparatus. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
p97/VCP inhibitor impacting ER-associated processes. DBeQ's potential indirect activation of FAM18A involves inhibiting p97/VCP, impacting ER-associated processes and Golgi membrane dynamics. Its role in modulating ER-associated processes could influence Golgi apparatus function and contribute to FAM18A activation within the Golgi membrane environment. Understanding the interplay between p97/VCP inhibition and FAM18A activation sheds light on potential regulatory mechanisms within the Golgi apparatus. | ||||||